Table 4 Predictive factors of the 2-year PFS in univariate analysis
Variables | Univariate analysis | ||
|---|---|---|---|
HR | 95% CI | p-value | |
Age | 0.95 | (0.91, 1.00) | 0.03 |
FIGO stage | 0.67 | (0.34, 1.34) | 0.26 |
Lymph node metastasis | |||
Negative | 1.00 | – | – |
Positive | 2.13 | (0.65, 6.91) | 0.21 |
Distant metastasis | |||
Negative | 1.00 | – | – |
Positive | 0.00 | (0.00, ∞) | 0.99 |
EBRT dose at the external os | 1.04 | (0.98, 1.11) | 0.17 |
HDR-ICBT dose at the external os | 1.01 | (0.99, 1.03) | 0.28 |
Chemotherapy | |||
0 mg/m2 | 1.00 | – | – |
≥ 100 mg/m2 | 1.01 | (0.99, 1.02) | 0.35 |
PD-1 expression levels | 1.15 | (0.72, 1.84) | 0.56 |
PD-L1 expression levels | 1.02 | (1.00, 1.05) | 0.09 |
CD8 expression levels | 1.08 | (0.95, 1.22) | 0.24 |
CD68 expression levels | 1.02 | (0.99, 1.04) | 0.26 |
CD163 expression levels | 1.03 | (1.00, 1.06) | 0.09 |
FoxP3 expression levels | 1.17 | (0.65, 2.11) | 0.61 |
HIF-1α expression levels | 0.99 | (0.96, 1.02) | 0.52 |